Hesco will take 2 billion injection varieties to join Forces Hengrui, Zhengda Sunny siege of Merca East.

Pharmaceutical Network August 14th, recently, Hesco's injection acetate capofen net 6 imitation listing applications have entered the "in the approval" stage, is expected to usher in good news.
the product was developed by Merca East, the current approved domestic enterprises are Hengrui, Zhengda Tianqing and Berry Pharmaceuticals.
Figure 1: Hesco's net registration progress for injection acetate capofen Source: CDE Official Website Figure 2: Mercadon Capofen Net Global Sales (units: US$ million) Source: Minet Multinational Listed Companies Sales Database Capofen Net Echinin Drug, a type of Semi-synthetic lipid peptides, which play a bactericidal role by inhibiting the synthesis of beta-(1,3)-D-glucosamine, are used to treat neotromocyte reduction, suspected fungal infections in patients with fever, and to treat invasive asmycinoma patients who are ineffective or insatiable for other treatments.
's Capofen net was approved by the FDA in January 2001, and global sales peaked at $680 million in 2014.
original research products entered China in 2002, Hengrui's six-class generic listing application was approved in 2017, becoming the first domestic generic;
Figure 3: 2019 China's public medical institutions terminal Capofen net enterprise competition source: Minet China's public medical institutions terminal competition pattern injection acetic acid carpocine net is a body-wide antifellar drug heavy varieties, MiNet data show that the product in 2019 in China's urban public hospitals, county-level public hospitals, urban community centers and township hospitals (referred to as China's public medical institutions) terminal sales of more than 2 billion yuan.
with the domestic generic drugs have been approved for listing, the market share of the original research company Mercadon has declined significantly, with 98.45 percent, 90.95 percent and 84.57 percent, respectively, in 2017-2019.
has a time advantage in the first generic listing, the market share continues to climb, in 2019 has increased by 15%.
figure 4: Currently in the trial of injection acetate capofen net source: Mi net MED2.0 China drug review database is currently, Osaikang, Central and Eastern China and other 5 categories of six types of imitation listing applications in the review and approval, in addition, Qilu's 4 types of imitation listing applications are also under review, currently only Hengrui declaration of consistent evaluation of supplementary applications, finally Qilu successfully approved and won the first review, or Hengrui continued to maintain the domestic leadership advantage? We'll see.
: CDE official website, Minet database review data statistics as of August 13, 2020, if there are errors, please point out.
.